Inotec AMD

Executive Summary

Inotec AMD Ltd., based in Cambridge, UK, is a medical device company focused on advanced wound care. Its flagship product, the NATROX® O₂ system, is a wearable device that delivers continuous topical oxygen therapy (cTOT) directly to chronic, hard-to-heal wounds 24/7. The device is designed for ease of use by patients, aiming to improve healing outcomes where standard care has failed. Chronic wounds, such as diabetic foot ulcers and pressure ulcers, represent a significant burden on healthcare systems globally, with limited effective treatment options. Inotec’s technology addresses this unmet need by providing a non-invasive, patient-friendly solution that enhances oxygenation at the wound site, promoting tissue repair and infection control. The company's focus on simplifying therapy for home use could drive adoption and reduce healthcare costs. Inotec has positioned NATROX as a potential standard-of-care adjunct for chronic wound management. The system has been evaluated in clinical studies demonstrating accelerated healing and high patient compliance. As the company seeks to expand its commercial footprint, key near-term catalysts include regulatory approvals in major markets (e.g., FDA clearance for diabetic foot ulcers), publication of pivotal trial data, and strategic partnerships with wound care distributors or healthcare providers. With a strong clinical rationale and growing demand for cost-effective wound care solutions, Inotec AMD is poised for growth, though it faces competition from other oxygen therapy and advanced wound care modalities. Its ability to secure regulatory and reimbursement milestones will be critical for scaling adoption.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for NATROX O₂ system for diabetic foot ulcers70% success
• Q2 2026Publication of pivotal clinical trial results showing improved healing rates compared to standard care80% success
• Q3 2026Exclusive distribution partnership with a major wound care company in the US or EU60% success